Skip to main content

Table 2 Clinical characteristics of GBM splicing types

From: Classification of glioma based on prognostic alternative splicing

 

ST1(n = 49)

ST2(n = 49)

ST3(n = 56)

Total(n = 154)

Clinical

 Age

  Median

62.8

60.1

61.0

60.24

  No. ≤ 40 years old

1

5

6

12

Survival (in months)

 Median (CI)

9.0 (5.47, 12.8)

15.1 (13.5, 17.7)

15.6 (13.5–25.5)

13.8 (12.1–15.3)

Disease-free survival (in months)

 Median (CI)

8.4 (6.0, NA)

8.5 (6.7 13.1)

11 (5.9, NA)

8.5 (6.7, 13)

Karnofsky score

 100

2

2

7

11

 90

0

2

0

2

 70–80

19

25

19

63

  < 70

8

6

16

30

Sex

 Female

18

20

16

54

 Male

31

29

40

100

Molecular

 IDH Status

  Mutant

0

3

7

10

  WT

46

45

49

140

 MGMT Promoter

  Methylated

11

17

24

52

  Unmethylated

26

24

21

71

 G-CIMP Methylation

  G-CIMP

0

2

6

8

  Non-G-CIMP

48

46

50

144

 TERT Promoter

  Mutant

4

9

12

25

  WT

45

39

41

4

 TERT Expression

  Expressed

38

42

47

127

  Not.expressed

10

7

9

26

 CHR7 Gain CHR10 loss

  Gain chr7&loss chr10

31

32

34

97

  No combined CNA

18

13

20

51

 CHR19/20 co gain

  Gain chr19/20

2

5

12

19

  No chr19/20 gain

47

40

42

129

Clusters

 Transcriptome Cluster

  CL

49

26

7

1

  MC

66

16

8

6

  NE

5

1

19

9

  PN

18

3

72

61

 Original Cluster

  Classical

39

0

0

0

  G-CIMP

7

0

1

0

 IDHmut-codel

0

1

23

20

  IDHmut-non-codel

0

4

127

67

  IDHwt

0

49

21

6

  Mesenchymal

50

0

0

0

  Neural

26

0

0

0

  Proneural

29

0

0

0

 Pan-Glioma RNA Expression Cluster

  LGr1

20

4

25

17

  LGr2

3

0

0

2

  LGr3

9

4

127

68

  LGr4

121

46

20

6

 Pan-Glioma DNA Methylation Cluster

  LGm1

7

4

18

11

  LGm2

1

0

120

59

  LGm3

0

1

14

19

  LGm4

43

14

4

0

  LGm5

59

30

12

0

  LGm6

12

5

5

5